NCT04592198 2025-03-24
Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Xiamen LP Pharmaceutical Co., Ltd
Phase 2 Completed
Clinical Trials
10 trialsNCT03204279 2024-06-25
CINV
Helsinn Healthcare SA
Phase 2 Completed
NCT03097588 2021-07-12
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00900757 2019-08-28
Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide
Duke University
Phase 2 Completed
NCT03862144 2019-03-05
GIM15-NEPA
Consorzio Oncotech
Phase 2 Completed
NCT00381862 2017-06-12
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00600353 2017-03-09
Multi-day Doses in Prevention of Nausea and Emesis
University of Kansas Medical Center
Phase 2 Completed
NCT00306735 2016-12-05
Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.
Eisai Inc.
Phase 2 Completed
NCT01909856 2015-12-04
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT00666783 2008-04-25
An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients
Xijing Hospital
Phase 2 Completed